Page last updated: 2024-09-04

olmesartan and benzbromarone

olmesartan has been researched along with benzbromarone in 5 studies

Compound Research Comparison

Studies
(olmesartan)
Trials
(olmesartan)
Recent Studies (post-2010)
(olmesartan)
Studies
(benzbromarone)
Trials
(benzbromarone)
Recent Studies (post-2010) (benzbromarone)
84118555448259208

Protein Interaction Comparison

ProteinTaxonomyolmesartan (IC50)benzbromarone (IC50)
envelope glycoproteinHuman immunodeficiency virus 112.8
nuclear receptor corepressor 2 isoform 2Homo sapiens (human)4.811
peroxisome proliferator-activated receptor gamma isoform 2Homo sapiens (human)4.811
Adenosine receptor A3Homo sapiens (human)5.222
60 kDa heat shock protein, mitochondrialHomo sapiens (human)9.1
Cytochrome P450 2C9 Homo sapiens (human)1.0895
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)5.222
Mitogen-activated protein kinase 1Homo sapiens (human)1.946
Multidrug resistance-associated protein 1 Homo sapiens (human)4
5-hydroxytryptamine receptor 2BHomo sapiens (human)1.804
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)5.222
Cytochrome P450 2J2Homo sapiens (human)4.26
10 kDa heat shock protein, mitochondrialHomo sapiens (human)9.1
Aldo-keto reductase family 1 member C1Homo sapiens (human)0.048
Mitogen-activated protein kinase 14Homo sapiens (human)1.235
Solute carrier family 22 member 6Homo sapiens (human)4.6
Monocarboxylate transporter 2Rattus norvegicus (Norway rat)9
Solute carrier family 22 member 12Homo sapiens (human)0.8695
Eyes absent homolog 3Homo sapiens (human)8.3
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.2
M17 leucyl aminopeptidasePlasmodium falciparum 3D781.89
M1-family alanyl aminopeptidasePlasmodium falciparum 3D762.78

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ekins, S; Williams, AJ; Xu, JJ1
Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T1
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ1

Other Studies

5 other study(ies) available for olmesartan and benzbromarone

ArticleYear
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5

    Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents

2011
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7

    Topics: Glutathione; Pharmacology; Sulfur Radioisotopes

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:1

    Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity

2013